News Agency
The Times

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

  • Written by PR Newswire
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001)

– Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and over 70% of patients in TANDEM (Fixed Dose Combination Obicetrapib...

Read more: Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY TANDEM Clinical...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion